Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Rivastigmine prevention of delirium · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Rivastigmine prevention of delirium | DRUG | - |
Inclusion Criteria: * Patients undergoing cardiac surgery with use of extracorporeal circulation * Aged 65 or more Exclusion Criteria: * "redo" procedures * anticipated use of succinylcholine during operation * contraindications to rivastigmine * preoperative mini mental score \< 15
Rivastigmine is being studied for the prevention of delirium, specifically postoperative delirium in patients undergoing cardiac surgery. The Phase 3 trial NCT00257868 evaluated rivastigmine for this use in patients aged 65 years and older in Switzerland. It is not approved for delirium prevention.
Rivastigmine is a small molecule inhibitor of the enzymes acetylcholinesterase (ACHE) and butyrylcholinesterase (BCHE). By inhibiting these enzymes, it reduces the breakdown of acetylcholine, which may help maintain cholinergic signaling. This mechanism is being investigated for the prevention of delirium.
Novartis AG (ticker: NVS) is the developer of rivastigmine for the prevention of delirium. The company sponsored the Phase 3 trial evaluating this use.
Rivastigmine for the prevention of delirium is in Phase 3 development. The single Phase 3 trial, NCT00257868, has been completed. The drug is investigational for this indication and has not been approved for delirium prevention.
One clinical trial has evaluated rivastigmine for delirium: NCT00257868, titled "Rivastigmine for the Prevention of Postoperative Delirium in Patients Undergoing Cardiac Surgery." This completed Phase 3 trial enrolled 120 patients aged 65 years and older in Switzerland. It was randomized and double-blind.